About Biocatalyst Consulting
Founder-led. Network-powered.
Biocatalyst is built differently to give clients senior scientific, strategic, and creative expertise without the overhead or rigidity of a traditional agency model.
Every engagement starts with better questions: What are you trying to achieve? Who needs to understand the science? What are the technical, commercial, budget, and timeline constraints? What does success look like?
From there, we build the right approach and bring in the right collaborators when needed. Some projects need strategy. Others need technical writing, design, video, campaign support, customer insight, or specialized scientific expertise. Many need a mix.
The result is flexible, focused support built around the problem, not a fixed agency roster.
Meet the founder
Matt Ferris, PhD, is the founder and president of Biocatalyst Consulting. He brings a rare combination of scientific depth, marketing leadership and business strategy and creative execution to life science companies and investors.
Matt earned his PhD in bioanalytical chemistry from the University of Colorado Boulder and his BS in Chemistry with a Biochemistry option from Fort Lewis College. His scientific background and experience spans diverse methods (e.g., spectroscopy, electrochemistry, PCR, GC/MS, cloning, sequencing), applications (e.g., molecular biology, gene editing, diagnostics, personalized medicine) and product types (e.g., platforms, instruments, reagents, service providers).
Before founding Biocatalyst, Matt held roles at Thermo Fisher Scientific, GE Healthcare, Plexus, InDevR, Particle Measuring Systems, and Los Alamos National Laboratory. His experience spans startups, national labs, large life science corporations, and venture capital.
Today, Matt helps clients understand their audiences, clarify their value, shape their message, and create content and campaigns that are technically credible, strategically useful, and built to support real business goals.
Selected career highlights
Built Biocatalyst Consulting from the ground up to provide technical, marketing, and strategic support for life science companies and investors.
Managed a $7M annual marketing budget at Thermo Fisher Scientific and helped deliver $1.2M in efficiency savings.
Managed a $43M portfolio of RNAi, gene expression, and CRISPR gene editing products at GE Healthcare Dharmacon.
Directed Dharmacon’s entry into CRISPR-Cas9 gene editing with 10+ new product introductions and $1M incremental revenue within one year.
Led development and commercialization of InDevR’s Virus Counter® system, acquired by Sartorius in 2016.
Served as acting principal investigator for NIH/NIAID Phase I and Phase II SBIR grants.
Holds patents related to scientific technologies and consumer products.